Cagan Ross
Icahn School of Medicine at Mount Sinai, Annenberg 25-40, Campus Box 1020, 1468 Madison Avenue, New York, NY 10029, USA
Dis Model Mech. 2016 Nov 1;9(11):1241-1244. doi: 10.1242/dmm.028159.
An increasing number of laboratories that focus on model systems are considering drug screening. Executing a drug screen is complicated enough. But the path for moving initial hits towards the clinic requires a different knowledge base and even a different mindset. In this Editorial I discuss the importance of doing some homework before you start screening. 'Lead hits', 'patentable chemical space' and 'druggability' are all concepts worth exploring when deciding which screening path to take. I discuss some of the lessons I learned that may be useful as you navigate the screening matrix.
越来越多专注于模型系统的实验室正在考虑进行药物筛选。执行一次药物筛选已经够复杂的了。但是将最初筛选出的活性物质推进到临床阶段需要不同的知识基础，甚至是不同的思维方式。在这篇社论中，我讨论了在开始筛选之前做好一些准备工作的重要性。在决定采取哪种筛选途径时，“先导活性物质”“可专利的化学空间”和“成药性”都是值得探索的概念。我将讨论一些我学到的经验教训，这些经验教训在您梳理筛选矩阵时可能会有所帮助。
